Shiu W, Leung N, Li M, Leung W T, Li A K
Department of Clinical Oncology, Chinese University of Hong Kong, Shatin.
Jpn J Clin Oncol. 1988 Sep;18(3):235-7.
An open phase II study of high-dose 4'epidoxorubicin (90 mg/m2) was conducted in 33 patients with inoperable hepatocellular carcinoma. Three out of the 33 (9%) patients showed tumour response. The treatment was relatively well tolerated with a moderate degree of haematological toxicity and alopecia, and a mild degree of nausea and vomiting. The overall median survival was 72 days with a prolongation in the patients who showed some response.
对33例无法手术的肝细胞癌患者进行了一项大剂量表阿霉素（90mg/m²）的开放性II期研究。33例患者中有3例（9%）出现肿瘤反应。该治疗耐受性相对较好，血液学毒性和脱发程度中等，恶心和呕吐程度较轻。总体中位生存期为72天，有反应的患者生存期延长。
